Drugdocs | Perfluorohexyloctane

Drug updated on 4/16/2024

Dosage Form	Ophthalmic solution (topical; 100% perfluorohexyloctane)
Drug Class	Semifluorinated alkanes
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Perfluorohexyloctane (Miebo) is indicated for the treatment of signs and symptoms associated with Dry Eye Disease (DED), demonstrating effectiveness in improving key indicators such as eye dryness score, ocular surface disease index, lipid layer thickness, and total corneal fluorescein staining.
The information was derived from a single study categorized under Systematic Reviews / Meta-Analyses.
Compared to control groups or other treatments for DED, Miebo showed superior performance in almost all studied variables except tear film break-up time where controls had a slight advantage. This suggests potential benefits from combination therapy or additional interventions targeting this specific aspect.
In terms of safety profile, perfluorohexyloctane has been associated with a low incidence of treatment-emergent adverse events, indicating it as potentially safer than traditional substitutes or anti-inflammatory medications used for DED, which may have more significant side effects.
High patient satisfaction was noted during the use of Miebo, suggesting its suitability for long-term management strategies required by chronic conditions like DED.
While no specific subgroup analyses were detailed, findings suggest broad applicability across different patient subsets; however, future research could help clarify its benefits specifically tailored towards certain demographics.

Document Title	Year	Source
Miebo (perfluorohexyloctane) Prescribing Information.	2023	Bausch & Lomb Americas Inc., Bridgewater, NJ

Document Title	Year	Source
Perfluorohexyloctane in dry eye disease: a systematic review of its efficacy and safety as a novel therapeutic agent.	2023	The Ocular Surface